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Adenine Nucleotide Translocase 1 Deﬁciency
Results in Dilated Cardiomyopathy With Defects
in Myocardial Mechanics, Histopathological
Alterations, and Activation of Apoptosis
Nupoor Narula, BS,*† Michael V. Zaragoza, MD, PHD,*‡ Partho P. Sengupta, MBBS,
Peng Li, MD, PHD,§ Nezam Haider, PHD,§ Johan Verjans, MD,§ Katrina Waymire, MA,†
Mani Vannan, MD,§ Douglas C. Wallace, PHD*†‡
Irvine, California; and Scottsdale, Arizona
O B J E C T I V E S The aim of this study was to test the hypothesis that chronic mitochondrial energy
deﬁciency causes dilated cardiomyopathy, we characterized the hearts of age-matched young and old
adenine nucleotide translocator (ANT)1 mutant and control mice.
B A C KG ROUND ANTs export mitochondrial adenosine triphosphate into the cytosol and have a
role in the regulation of the intrinsic apoptosis pathway. Mitochondrial energy deﬁciency has been
hypothesized, on the basis of indirect evidence, to be a factor in the pathophysiology of dilated
cardiomyopathies. Ant1 inactivation should limit adenosine triphosphate for contraction and calcium
transport, thereby resulting in early cardiac dysfunction with later dilation and heart failure.
METHOD S We conducted a multiyear study of 73 mutant (Ant1/) and 57 control (Ant1/)
mice, between the ages of 2 and 21 months. Hearts were characterized by cardiac anatomy,
echocardiographic imaging with velocity vector analysis, histopathology, and apoptosis assays.
R E S U L T S The Ant1/ mice developed a distinctive concentric dilated cardiomyopathy, charac-
terized by substantial myocardial hypertrophy and ventricular dilation, with cardiac function declining
earlier in age as compared to control mice. Left ventricular circumferential, radial, and rotational
mechanics were reduced even in the younger mutants with preserved systolic function. Histopathologic
analysis demonstrated increased myocyte hypertrophy, ﬁbrosis, and calciﬁcation in the mutant mice as
compared with control mice. Furthermore, increased cytoplasmic cytochrome c levels and caspase 3
activation were observed in the mutant mice.
CONC L U S I O N S Our results demonstrate that mitochondrial energy deﬁciency is sufﬁcient to
cause dilated cardiomyopathy, conﬁrming that energy defects are a factor in this disease. Energy
deﬁciency initially leads to early mechanical dysfunction before a decline in left ventricular systolic
function. Chronic energy deﬁciency with age then leads to heart failure. Our results now allow us to use
the Ant1/mouse model for testing new therapies for ANT1 mutant patients. (J Am Coll Cardiol Img
2011;4:1–10) © 2011 by the American College of Cardiology Foundation
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2itochondria generate adenosine triphos-
phate by oxidative phosphorylation.
The resulting matrix adenosine triphos-
phate is exchanged across the mito-
hondrial membrane for cytosolic adenosine
iphosphate by the adenine nucleotide translocators
ANTs) (1). Nuclear-encoded ANTs are 30-kDa
ransmembrane polypeptides proposed to function
s homodimers (2). Certain ANT isoforms also play
role in the regulation of apoptosis through mod-
lating the mitochondrial permeability transition
See page 11
ore (3–5). Animals harbor up to 4 ANT isoforms,
hich exhibit differential tissue-specific and tempo-
al expression patterns. In both human and mouse,
soform 1 (ANT1, human; Ant1, mouse) is predom-
inantly expressed in high-energy tissues,
including heart, muscle, and brain (6–8).
In humans, ANT1 null, autosomal re-
cessive mutations cause mitochondrial
myopathy and cardiomyopathy (9). Anti-
bodies against ANT have been commonly
observed in patients with dilated cardio-
myopathy (10). These observations impli-
cate ANT1 in the etiology of cardiomy-
opathy associated with dilation, reduced
function, and cardiomyocyte loss by apop-
tosis (11,12). Before the discovery of
ANT1-deficient patients, our laboratory
genetically inactivated Ant1 in the mouse.
The Ant1/ mice are viable and fertile;
however, they develop mitochondrial my-
opathy with hyperproliferation of abnor-
al mitochondria, ragged red muscle fibers, and
actic acidosis (13). This mouse Ant1 defect is also
ssociated with increased mitochondrial reactive
xidative species (ROS), antioxidant enzyme induc-
ion, and early accumulation of mitochondrial de-
xyribonucleic acid (mtDNA) mutations (14).
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5, 2010, accepted June 28, 2010.hese energetic and ROS aberrations are also
ssociated with the coordinate induction of both
tDNA and nuclear deoxyribonucleic acid genes
or mitochondrial biogenesis, induction of nuclear
eoxyribonucleic acid antioxidant and anti–
poptotic genes, and the downregulation of apop-
otic genes (15,16).
To test the hypothesis that chronic mitochon-
rial energy deficiency causes dilated cardiomyopa-
hy, we characterized the nature and progression of
he cardiomyopathy in Ant1-deficient mice. The
esults revealed that Ant1 deficiency is associated
ith a unique cardiomyopathy with significant ven-
ricular hypertrophy and chamber dilation, wherein
he deranged myocardial mechanics occur at an
arly age even before systolic dysfunction becomes
linically apparent.
E T H O D S
ice. We used homozygous Ant1B-geo mutant
Ant1/) and control (Ant1/) mice on
57BL/6J or 129S4 backgrounds. No clear differ-
nces were seen in results for the different back-
rounds. The Ant1 mutant mice and polymerase
hain reaction genotyping methods were as de-
cribed (13). All animal procedures were approved
y University of California Irvine Institutional An-
mal Care and Use Committee (#2002-2399).
ardiac imaging. Two-dimensional echocardiogra-
hy with M-mode and velocity vector imaging
VVI) (Amid, Italy, and Siemens, Mountain View,
alifornia), were performed on 73 mutant and 57
ontrol mice (ages 2 to 21 months; 63 female and
7 male). The animals were anesthetized and ven-
ilated with 98% oxygen and 2% isoflurane. Elec-
rocardiography leads were applied to monitor heart
ate and trigger echo image acquisitions. Ultra-
ound images were obtained with a 12-MHz fre-
uency linear phased probe (Sequoia, Siemens), in
eft ventricular (LV) short-axis view at apex level.
oomed images were digitally captured. M-mode
mages at mid LV were used to determine left
entricular dimension at end-diastole (LVIDd) and
V dimension at end-systole. The LV ejection
raction (EF) was calculated. Interventricular sep-
um (IVS) wall thickness and left ventricular pos-
erior wall (LVPW) thickness were obtained, and
VS/posterior wall ratio was determined. Echocar-
iograms in DICOM 4.0 format were analyzed
ith Research Arena (TomTec, Unterschleissheim,
ermany) based 2-dimensional VVI package (Ver-B B R E V I A T I O N S
N D A C R O N YM S
NT adenine nucleotide
ranslocator
V left ventricle/ventricula
VI velocity vector imagin
VIDd left ventricular
imension at end-diastole
F ejection fraction
VS interventricular septu
VPW left ventricular
osterior wall
tDNAmitochondrial
eoxyribonucleic acidion 3.702, Siemens). The endocardial and epicar-
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3ial borders were manually identified in a single
rame of a cine-loop, and the borders in other
rames were automatically generated. Segmental
eak systolic velocity, diastolic velocity, radial
train, and circumferential strain were obtained by
VI. Accuracy of VVI for testing myocardial de-
ormation in experimental settings has been done
reviously (17).
istopathology. Of 130 mice imaged, 72 (ages 2 to 19
onths; 20 males and 52 females) underwent his-
opathologic analysis. Cardiac tissue was fixed in
ither formalin or paraformaldehyde, paraffin-
mbedded, and sectioned (7 m). Sections were
tained with hematoxylin and eosin. Sections from
9 mice were also stained with Masson’s Trichrome.
estern blot analysis. Heart samples (50 mg) from 3
utants and 3 control mice, ages 14 to 21 months,
ere diced and solubilized in 210 mmol/l mannitol,
0 mmol/l sucrose, 1 mmol/l ethylene glycol tet-
aacetic acid, 5 mmol/l HEPES pH 7.4, and 110
g/l digitonin for 5 min. The samples were
entrifuged at 10,000 rpm for 10 min at 4°C,
nd the supernatant protein concentration was de-
ermined by the BioRad Protein Assay reagent
BioRad, Hercules, California). Samples were
ead spectrophotomically at   595 nm with
pectronic Genesys 2 (Thermo Fisher Scientific,
altham, Massachusetts). Samples were boiled for
min, and proteins were separated on 15% SDS-
olyacrylamide gel (8-cm length) with Tris-glycine
uffer. After blotting, membranes were processed
ith first step antibody. We used mouse antibodies:
onoclonal anti–cytochrome-c (PharMingen In-
ernational, San Diego, California); polyclonal anti-
aspase 3 (Biotechnology, Santa Cruz, California);
nd monoclonal anti-GAPDH (Chemicon Inter-
ational, Temecula, California). Second-step anti-
ody was polyclonal anti-mouse IgG conjugated to
orseradish peroxidase (Amersham Biosciences,
an Diego, California).
tatistical analysis. We used JMP version 7.0 (SAS
nstitute, Cary, North Carolina) and GRAPHPAD
RISM software (GraphPad Software, La Jolla,
alifornia). Student t test was employed for mean
alues. For 3-group analyses, no corrections were
ade for multiple comparisons. To compare the
istopathologic findings between control mice and
utants, Pearson chi-square tests of 2  2 contin-
ency tables were used; a 2  3 contingency table
as used to compare the 3 categories of hypertro-
hy (none, mild, and moderate-to-severe). Two-tail
value was used for histopathologic analysis, and-tail p value was used for biochemical analysis. We Eonsidered values of p  0.05 as a significant
ifference. Due to heterogeneity of variance in the
iochemical data, both parametric and nonparamet-
ic tests and the Welch t test were employed.
Echocardiographic parameters of LV mechanics
ere correlated with LVEF with Pearson correla-
ion coefficient (R) with p value. The diagnostic
ccuracy of echocardiographic parameters of LV
echanics for differentiating mutant from control
ice was quantified with receiver-operator charac-
eristic analysis. Area under the curve was calculated
18) with binomial confidence interval and com-
ared with the method of DeLong et al. (19) with
edCalc Software (Mariakerke, Gent, Belgium).
E S U L T S
nt1 cardiomyopathy: concentric hypertrophy with
ilation. M-Mode echocardiographic images of
ontrol and mutant hearts are shown in Figure 1A.
y averaging the data (Table 1), we observed an
ncrease in heart weight and heart/body-weight
atio and LVIDd, IVS, and LVPW thickness in
utant animals, indicative of LV dilation and
oncentric myocardial hypertrophy. Fractional
hortening and EF were reduced in mutant hearts,
ndicating presence of LV systolic dysfunction (Ta-
le 1).
Mutant mice displayed significant regional de-
ects in myocardial contraction. Examples are
hown for control and mutant hearts in Figures 1B
nd 1C. Circumferential and radial strains, rota-
ion, and rotational velocity for control versus mu-
ant hearts are shown in Table 1. Mutant hearts
emonstrated 40% reduction in rotation, 25% re-
uction in rotational velocity, and more than 50%
ecrease in circumferential and radial strain devel-
pment, all highly significant.
ge-related progression of Ant1 cardiomyopathy.
ur results showed that mutant hearts are in
ggregate abnormal in all contractile parameters but
ith considerable variability. Because we examined
nimals from ages 2 to 21 months, this variability
ould be the result of variable penetrance of the
utation or age-related decline in cardiac function
n mutant hearts. To investigate this, we analyzed
he EF of control and mutant hearts by age (Fig. 2).
his suggested that the average EF of control
earts increased throughout life (B coefficient 
0.39, p  0.056). By contrast, EF of mutant
earts declined with age (B coefficient 0.79,
 0.029). There was also significant variability in
F in each age group, greater in mutant than in
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4Figure 1. Cardiomyopathy in Ant1/ Mouse
(A) M-mode echocardiography. Ultrasound images depict left ventricular dimensions in a control (upper panel) and mutant (bottom panel) mouse. Interventricular septum (IVS)
thickness is shown as distance between blue and red lines, and left ventricular internal dimension at end-diastole (LVIDd) is shown as distance between red and yellow lines.
The LVIDd is increased from 3.3 mm in control to 3.9 mm in mutant. (B) Velocity vector imaging: radial and rotational velocity vectors. Left ventricular short axis in control (a–c)
and Ant1 mutant (d–f). Endocardial velocity vectors (a and d) were attenuated at end-ejection in mutant. The 2-dimensional maps of radial velocity and the apical rotational
velocity are presented in adjacent panels. In contrast to the uniform pattern of radial velocities seen in control mice (b), marked dyssynchrony is seen in the mutant animal (e).
Similarly, the velocity of counterclockwise rotation in systole is biphasic in the control mice (c) but is dyssynchronous in the mutant animal (f). (C) Velocity vector imaging: veloc-
ity, strain, and strain rates. Images from control (upper panels) and mutant (bottom panels). For each heart, velocity (a and d), strain (b and e), and strain rates (c and f) are
depicted by 3-dimensional color mapping. Uniform motion and shortening are observed in control, whereas dyssynchronous motion and shortening are delineated in the veloc-
ity, strain, and strain rate curves of mutant.
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5ontrol hearts (Fig. 2). The LVEF in mutants and
ontrol mice across all ages correlated with circum-
erential strain, radial strain, rotation, and rotational
elocity in systole and diastole (R 0.73, R 0.65,
 0.79, R  0.74, and R  0.71, respectively,
 0.001 for all).
To further evaluate the decline in cardiac func-
ion, we divided the mutant hearts into those that
ad EF within the range of control hearts (normal
F) and those that fell below the normal range
abnormal EF). We determined the mean and SD
f the EF of the control hearts and then selected the
F value that was 2 SDs below the control mean.
his lower cutoff value was an EF of 56%. With
pplication of this cutoff, 58% of the mutants
emonstrated EF below lower normal limits (Fig. 2,
otted line).
Next, we divided the mutant hearts into those
ith “normal EF” (n  31) and those with “abnor-
al EF” (n  42). We then recalculated the major
arameters (Table 2). The mean EF for control
ice, normal EF mutants, and abnormal EF mu-
ants was 71%, 65%, and 41%, respectively. The
VIDd of normal EF mutants and control mice
ere similar, whereas LVIDd of abnormal EF
utants was greater than control mice by 12%
Table 2). Normal EF mutants showed 40% in-
rease in IVS thickness, whereas abnormal EF
utants showed 44% increase in IVS thickness
Table 2).
We further characterized contraction mechanics
f LVs. Compared with control mice, both normal
F mutants and abnormal EF mutants showed
Table 1. Morphological and Echocardiographic Parameters in C
Parameters Control (n  57)
TBW (g) 39.39 9.65
Heart weight (g)* 0.21 0.05
Heart weight/TBW % 0.57 0.14
IVS (0.1 mm) 7.69 0.92
LVIDd (0.1 mm) 37.53 3.87
LVPW (0.1 mm) 7.59 0.87
IVS/LVPW 1.02 0.12
FS (%) 36.03 7.62
EF (%) 70.90 7.44
Rotation (°) 1.68 0.36
Rotation velocity (°/s) 45.68 9.35
CS (%) 12.01 2.12
RS (%) 11.96 2.60
Values are mean  SD. *Heart weights obtained for 61 of the 130 total mice (
CS  circumferential strain; EF  ejection fraction; FS  fractional shortening;
at end-diastole; LVPW  left ventricular posterior wall thickness; RS  radial steduction in LV rotational velocities, more markedor abnormal EF mutants (Table 2). Rotational
elocity of normal EF mutants was decreased only
1%, whereas that of abnormal EF mutants was
educed 60% (Table 2). Our analyses also revealed
triking differences in circumferential strain and
adial strain for the control and mutant hearts.
ompared with control mice, circumferential strain
as reduced in normal EF mutants (35%), and this
ifference was further exaggerated (60%) in abnor-
al EF mutants (Table 2). Radial strain of normal
F mutants was reduced (43%) and more profound
63%) in abnormal EF mutants, with all differences
tatistically significant (Table 2).
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Figure 2. EF Scatter Plot for Ant1 Mutants and Control Mice
Mutants (X) and control mice (circle). Abnormal ejection fraction (E
deﬁned as 2 SD below the average EF of control animals (dashed
zontal line). The best-ﬁt linear regression line is provided with R2 fo
ol and Ant1 Deﬁcient Mice
Mutant (n  73) p Value
30.89 4.47 0.0001
0.26 0.06 0.001
0.84 0.15 0.0001
10.90 1.56 0.0001
40.15 5.81 0.01
10.95 1.73 0.0001
0.99 0.08 0.1466
24.69 7.48 0.0001
51.05 15.01 0.0001
1.02 0.56 0.0001
34.01 10.81 0.0001
6.05 2.35 0.0001
5.41 2.23 0.0001
ntrol mice and 26 mutants).
interventricular septum thickness; LVIDd  left ventricular internal dimension
TBW  total body weight.= 0.065
= 0.064
F) is
hori-
r eachontr
35 co
IVS group. Sac  sacriﬁced.
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6In summary, mutant mice with normal EF,
espite having normal LVIDd, show subclinical
erturbations in contractile indexes. Although LV
otation has been previously shown to remain un-
ltered in hypertrophied hearts (20), LV hypertro-
hy in Ant1/ mutant hearts with preserved
VEF was associated with significantly reduced LV
pical rotation. This might suggest transmural dis-
ase (Table 2). Furthermore, all cardiac dysfunction
arameters declined with age in the mutant animals.
Table 3 shows the diagnostic accuracy of various
arameters of LV function for differentiating mu-
ant from control mice. Circumferential strain,
adial strain, and rotational velocity in diastole
howed greater area under the curve than EF for
ifferentiating mutants from control mice (p 
.02) (Table 3). For hearts with normal EF
56%), all 3 parameters showed good diagnostic
ccuracy for differentiating mutants from control
ice.
Table 2. Echocardiographic Parameters of LV Mechanics in Con
Obvious Systolic Dysfunction
Parameters Control (n  57)
EF % 70.90 7.44
Age 10.03 4.82
LVIDd (0.1 mm) 37.53 3.87
IVS (0.1 mm) 7.69 0.92
Rotation (degree) 1.68 0.36
Rotation velocity (degree/s) 45.68 9.35
CS % 12.01 2.12
RS % 11.96 2.60
Values are mean  SD. *Compared with normal group, p  0.0001; †compared
§compared with mutant normal EF group, p  0.05; compared with mutant n
Abbreviations as in Table 1.
ccuracy of Echocardiographic Parameters of LV Mechanics
AUC SE 95% CI p V
0.89 0.03 0.82 to 0.94 0
0.96* 0.01 0.91 to 0.98 0
0.96* 0.01 0.92 to 0.99 0
0.81* 0.03 0.73 to 0.87 0
0.77* 0.04 0.69 to 0.84 0
ocity 0.94* 0.02 0.89 to 0.97 0
0.91 0.03 0.84 to0.96 0
0.93 0.02 0.86 to0.97 0
0.63 0.06 0.52 to0.73 0
0.52 0.06 0.41 to0.62 0
ocity 0.88 0.03 0.79 to0.94 0ve; CI  conﬁdence interval; other abbreviations as in Table 1.ardiac morphology and histopathology. Increased
eart/body-weight ratios, IVS, and LVPW of mu-
ants all point to myocardial hypertrophy. Our
etailed hematoxylin and eosin analysis on 25
ontrol mice (ages 2 to 19 months) and 47 mutant
ice (ages 3 to 18.5 months) (Fig. 3) confirmed the
resence of myocyte hypertrophy. In addition, we
ound evidence of interstitial edema (Figs. 3A to 3D),
nterstitial inflammation, myocyte calcification,
inucleation, and myofibrillar lysis.
Myocyte hypertrophy was significantly more
ommon in mutants than in control mice [chi-
quare(2)  25.6, p  0.0001] (Fig. 4A). This was
lso true of mutant mice 12 months old [chi-
quare(2)  19.5, p  0.0001] (Fig. 4B). The dif-
erence in myocyte hypertrophy was lost in older
ice due to the increased presence of myocyte
ypertrophy in older (12 months) control mice.
ypertrophy seems to be an early finding of the
nt1/ heart.
and Ant1 Deﬁcient Mice With and Without
Mutant
Normal EF (n  31) Abnormal EF (n  42)
64.79 5.76* 40.90 11.09*†
10.18 3.79 12.95 5.26‡§
37.52 3.98 42.10 6.21*
10.77 1.50* 11.00 1.61*
1.50 0.26‡ 0.67 0.44*†
44.39 4.70 26.36 6.90*†
7.81 1.99* 4.75 1.66*†
6.80 2.09* 4.38 1.72*†
mutant normal EF group, p  0.0001; ‡compared with normal group, p  0.01;
al EF group, p  0.001.
Cutoff Sensitivity (%) Speciﬁcity (%)
64% 79.5 89.5
8.7% 87.7 96.5
7.7% 87.7 100.0
1° 49.3 100.0
31°/s 46.6 96.5
39°/s 94.5 78.5
9% 77.4 94.7
7.7% 77.4 100.0
1.6% 77.4 49.1
52°/s 100.0 24.6
39°/s 87.1 78.9trol
with
ormTable 3. Diagnostic A
Overall Group alue
EF 56% (abnormal) .001
CS* .001
RS .001
Rotation .001
Rotation velocity .001
Reverse rotation vel .001
EF 56% (normal)
CS .001
RS .001
Rotation .02
Rotation velocity .74
Reverse rotation vel .001
*Versus EF, p  0.02.
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7To examine fibrosis, we stained myocardial spec-
mens from 27 control mice (ages 2 to 19 months)
nd 42 mutants (ages 3 to 18.5 months) with
asson’s Trichrome (Figs. 5A to 5F). Fibrosis was
lassified as focal or multifocal and interstitial,
erivascular, or replacement (Figs. 4C and 4D).
verall, fibrosis was increased in mutant hearts
Fig. 4C), which became more evident and signif-
cant in older hearts (12 months) [chi-square(1) 
.5, p  0.05] (Fig. 4D). Moreover, multifocal inter-
titial fibrosis was significantly more frequent in older
utants, and multifocal replacement fibrosis was ex-
lusively observed in mutants (Figs. 4C and 4D).
ibrosis seems to be a later-stage phenomenon and
ccurs with greater frequency in mutants. Calcifica-
ion was also strikingly increased in mutants [chi-
quare(1)  20.8, p  0.0001] (Figs. 4A and 4B);
ccurrence of calcification was independent of age.
ctivation of apoptotic pathway in Ant1 mutant mice.
ytochrome c levels were found to be 6-fold higher
n the older mutants as compared with older control
ice (Fig. 6A). This could be due to the upregu-
ation of oxidative phosphorylation to compensate
or the chronic energy deficiency (16) or the syn-
hesis and release of mitochondrial cytochrome c or
oth. Caspase activation was evaluated on the basis
f the relative levels of the full length inactive
aspase 3 and the shorter cleaved and activated
aspase 3. Mutant hearts exhibited a 4-fold increase
n amount of full length caspase 3. In contrast to the
egligible levels in control myocardium, a large
roportion of cleaved and thus activated caspase 3
as observed in the mutant mice. The difference
as statistically significant for cytochrome c release
s well as active caspase 3 by application of para-
etric tests; however, due to small sample size and
eterogeneity of variance, the results were not
tatistically significant when nonparametric or
elch t tests were applied (Fig. 6B).
I S C U S S I O N
enetic inactivation of the Ant1 gene in the mouse
as been found to cause a unique cardiomyopathy
haracterized by substantial myocardial hypertrophy
nd ventricular dilation. Echocardiographic analy-
es of circumferential, radial, and rotational me-
hanics permitted detection of cardiac dysfunction
n Ant1-deficient mice when global determinants of
ontractility were still preserved, even as early as the
ge of 3 months. Although LV rotation is usually
ncreased or remains unaltered in hypertrophied
earts, LV hypertrophy in Ant1/ mutants with ereserved LVEF was associated with reduced LV
pical rotation, suggesting presence of transmural
isease. Early evidence of cardiac defects suggests
hat cardiac dysfunction might already be present in
he neonatal or prenatal period. This “latent” car-
iac dysfunction was confirmed by demonstration
f histological changes in all mutant hearts, regard-
ess of age. Mutant hearts had myocyte hypertro-
hy, myofibrillar lysis, edema, inflammation, and
alcification at all ages. Although none of these
eatures are individually pathognomonic, collec-
ively they have been reported in idiopathic dilated
ardiomyopathy. This pathology is associated with
ncreased activated-caspase 3, indicating that Ant1-
eficiency is accompanied by activation of apoptotic
athways; apoptosis has been reported in cardio-
yopathic hearts. This Ant1 deficiency cardiomy-
pathy seems unique, because it produces dilated
ardiomyopathy, which is associated with a sub-
tantial degree of concentric myocardial hypertro-
hy. Furthermore, this cardiomyopathy shows on-
et of mechanical dysfunction early on even when
ypertrophy is the predominant feature and global
ystolic function is normal.
The clinical relevance of our Ant1/ mutant
ouse model for human disease has been shown by
he recent report of a patient with a homozygous
ull missense (A123D) mutation in human ANT1
ene. This individual experienced mitochondrial
yopathy with ragged red fibers and exercise intol-
Figure 3. Histopathological Alterations in Mutant Animals
(A) Control, 7.5-month-old, with mild hypertrophy; (B) mutant, 9-mo
shows inﬂammation (boxed area) and calciﬁcation (circled area); (C
17-month-old, shows normal myocardial architecture with mild hyp
(white arrows); (D) mutant, 18-month-old, shows basophilic degene
(white arrow) and myoﬁbrillar lysis (triangles).nth-old,
) control,
ertrophy
rationrance together with a hypertrophic cardiomyopa-
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8hy. On echocardiography the patient was seen to
ave a concentric LV hypertrophy with comparably
hickened IVS and LVPW. The LV was not
ilated, and EF was still normal (9). In contrast to
his human case resulting from a homozygous null
utation (9), other cases of human disease resulting
rom ANT1 gene missense mutations are inherited
ith autosomal dominance; these mutations present
ith mitochondrial myopathy with progressive ex-
ernal ophthalmoplegia, in absence of cardiomyop-
Figure 4. Quantiﬁcation of Histopathologic Features
(A and B) Hematoxylin and eosin stained; (C and D) Masson’s trich
gate of data from mice 12 months old; (D) aggregate of data from
F  focal; Hyp  hypertrophy; Inﬂ  inﬂammation; Int  interstitia
replacement.
Figure 5. Cardiac Fibrosis by Masson’s Trichrome Staining
(A) Control, 8.5-month-old, shows multifocal interstitial ﬁbrosis; (B)
trol, 14.5-month-old, shows no ﬁbrosis; (D) mutant, 13.5-month-old
focal perivascular ﬁbrosis and focal interstitial ﬁbrosis (not seen her
multiple foci of interstitial ﬁbrosis.thy (21,22). Neither the ANT1 (A123D) patient
9) nor our mouse (23) exhibited evidence of oph-
halmoplegia and ptosis. Hence, the dominant
NT1 missense mutations in autosomal dominant
rogressive external ophthalmoplegia seem to be
cting as dominant negative mutations and are
enetically and phenotypically different from the
omozygous null mutations for cardiomyopathy.
erhaps the biochemical influence of the dominant
NT1 missense mutations is amplified through
stained; (A and C) aggregate of data from all ages; (B) aggre-
ice 12 months old. Binucl  binucleation; Calc  calciﬁcation;
 multifocal; MFL  myoﬁbrillar lysis; Per  perivascular; Rep 
ant, 5.5-month-old, shows multifocal replacement ﬁbrosis; (C) con-
ws multifocal interstitial ﬁbrosis; (E) control, 19-month-old, shows
F) mutant, 18.5-month-old, shows focal replacement ﬁbrosis androme
m
l; Mmut
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9heir inactivation in dimers with mutant subunits
ncorporated. Alternatively, dominant missense
utations might change ANT1 function, perhaps
aking it leakier for protons and thus reducing
nergy metabolism (24).
One of the most striking features of both the
utosomal recessive and autosomal dominant
NT1 diseases, in man and mouse, is the age-
elated accumulation of multiple mtDNA deletions.
he accumulation of multiple mtDNA deletions
as been documented in muscle for both the human
ominant and recessive cases (9,21) and in heart in
he Ant1/ mouse (14). These mtDNA rear-
angements have been proposed to result from
ucleotide imbalance (21) or excessive mtDNA
OS damage (13). Whatever the mechanism, the
ge-related accumulation of mtDNA damage
ight progressively erode mitochondrial energy
roduction, exacerbating the inherited ANT1 de-
ect and leading to the age-related progression of
he cardiomyopathy. If so, one therapeutic ap-
roach might be administration of mitochondrially
argeted antioxidants to inhibit mtDNA damage,
hus slowing disease progression.
We demonstrated initiation of intrinsic apoptosis
athway leading to the activation of caspase 3 in
utant hearts. This might indicate that apoptotic
rocesses contribute to the progression of the
NT1-deficient cardiomyopathy (25). Expression
Figure 6. Apoptosis Assays by Western Blot
(A) Increased cytochrome c levels in 3 mutants versus 3 control mice,
14 kDa, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  38
error bars are SEM. Inactive caspase 3  32 kDa, active caspase 3 
kDa  kilodaltons; SEM  standard error of the mean.f a caspase-8 fusion protein in the hearts of wransgenic mice resulted in activation of apoptosis
nd cardiomyopathy (26), and cardiomyocyte apop-
osis has been associated with dilated cardiomyop-
thy (27). Therefore, these observations suggest
hat therapies that stabilize the mitochondrial per-
eability transition pore, such as cyclosporin
-derivatives, might play a role in reducing pro-
ression of Ant1/ cardiomyopathy (28,29).
The most direct approach to treating the
NT1/ cardiomyopathy would be to replace the
issing ANT1 gene. We have been successful in
artially restoring ANT1 function in Ant1/
ouse muscle through transduction of the mouse
nt1 complementary deoxyribonucleic acid with
deno-associated virus. After transduction of the
uscle with the Ant1–adeno-associated virus, there
as a striking amelioration of the severe aspects of
keletal muscle pathology (30). By developing the
ouse Ant1/ model and performing detailed
haracterization of the cardiomyopathy, we are now
n position to evaluate relative benefits of various
herapeutic modalities.
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